Drugs / VNS vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06855160 | Apr 2025 → Sep 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNS vaccine | “Participants receive 1 dose of the candidate varicella vaccine (VNS vaccine), 1 dose of a measles, mumps, and rubella (MMR) vaccine, 1 dose of a hepatitis A virus (HAV...” NCT06855160 ↗ |
| Modality | Vaccine | “Investigational varicella vaccine administered intramuscularly.” NCT06855160 ↗ |
| Route | Intramuscular | “Investigational varicella vaccine administered intramuscularly.” NCT06855160 ↗ |